PBS updates

Keytruda (Pembrolizumab)

pembrolizumab 100 mg/4 mL injection, 4 mL vial · INJECTION · PBS code 13739D

STREAMLINED

What it costs

AU$3632.56 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2023-12-01.
  • • Repeats: 7.
  • • PBS program: IN.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage II or Stage III triple negative breast cancer


The treatment must be initiated in combination with neoadjuvant chemotherapy; AND

The condition must not have progressed/recurred whilst on treatment with this drug; AND

Patient must not be undergoing treatment with this drug beyond 52 cumulative weeks under this restriction; AND

Patient must be undergoing treatment with this drug administered once every 3 weeks - prescribe up to 7 repeat prescriptions; or

Patient must be undergoing treatment with this drug administered once every 6 weeks - prescribe up to 4 repeat prescriptions.

Sponsor: Merck Sharp & Dohme (Australia) Pty Ltd ABN 14 000 173 508

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.